BioCentury - Ascenta Therapeutics Inc. - Company Profile
Ascenta Therapeutics Inc. Completed. 04/10/2007. Venture (Series C financing). $30000000. Ascenta Therapeutics Inc. Completed. 11/18/2004 ...
http://www.biocentury.com/companies/Ascenta_Therapeutics_Inc...
|
Ascenta Therapeutics Inc. Raises $50 Million in Series C Financing ...
SAN DIEGO--(BUSINESS WIRE)--Ascenta Therapeutics, Inc. today announced that it has raised $50 million in a Series C round of financing, with $30 million ...
http://www.biospace.com/news_story.aspx?NewsEntityId=51756...
|
BioPortfolio - Ascenta Therapeutics Inc.
Ascenta Therapeutics Inc. - Entry on Bioportfolio's Biocorporate Database.
http://www.bioportfolio.com/biocorporate/18775-Ascenta_Thera...
|
BioSpace - Ascenta Therapeutics Inc. News, Search Jobs, Events
Ascenta Therapeutics Inc. Highlights Multiple Data Presentations at This Week's AACR-NCI-EORTC International Conference in San Francisco 10/24/2007 9:56:26 ...
http://www.biospace.com/company_profile.aspx?CompanyId=10010...
|
Summary of OREXIGEN THERAPEUTICS, INC. - Yahoo! Finance
10 Nov 2008 ... He is Chairman of the Board at Ascenta Therapeutics, Inc., Calixa Therapeutics, Ocera Therapeutics Inc., Sequel Pharmaceuticals, Inc., ...
http://biz.yahoo.com/e/081110/orex8-k.html...
|
Clinical Data On Ascenta Therapeutics Inc. Lead Product AT-101 ...
ATLANTA, June 5 /PRNewswire/ -- Ascenta Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company today announced the presentation of ...
http://www.biospace.com/news_story.aspx?NewsEntityId=20792...
|
UMHS Press Release: Researchers find potential cancer drug
3 Mar 2008 ... Ascenta is committed to advancing MI-219, which we have designated AT-219, ... Ming Guo, and Dajun Yang from Ascenta Therapeutics Inc. ...
http://www.med.umich.edu/opm/newspage/2008/cancerid.htm...
|
Ascenta Therapeutics Inc. AT-101 Clinical Trial Data Presented At ...
18 /PRNewswire/ -- Ascenta Therapeutics Inc., a privately-held clinical stage biopharmaceutical company today announced the presentation of its lead ...
http://www.biospace.com/news_story.aspx?NewsEntityId=3201...
|
Article : SciBX: Science-Business eXchange
Ascenta Therapeutics Inc. has at least one other MDM2 inhibitor, MI-147, ... Patent application filed; technology licensed to Ascenta Therapeutics Inc. ...
http://www.nature.com/scibx/journal/v1/n8/full/scibx.2008.18...
|
AT-101, Ascenta Therapeutics Inc.'s Oral Pan-Bcl-2 Inhibitor ...
ATLANTA, June 7 /PRNewswire/ -- Ascenta Therapeutics lead clinical compound AT- 101 has been chosen as one of the Top Ten Leading Cancer Projects in a survey
...
http://www.biospace.com/news_story.aspx?NewsEntityId=20973...
|
